Tirzepatide vs sleeve gastrectomy

A 2026 retrospective study compared 12-month weight loss after sleeve gastrectomy with weight loss during tirzepatide treatment in a diverse urban cohort with severe obesity. After matching patients on measured characteristics, sleeve gastrectomy was associated with 30% total weight loss at 12 months, compared with 12% in the tirzepatide group^[1]. The result describes one selected cohort. It does not prove that surgery is the better choice for every person.

What the researchers compared

The investigators reviewed records from a single centre rather than assigning treatment at random. One group received tirzepatide, a medicine that activates GIP and GLP-1 receptors. The other underwent sleeve gastrectomy, an operation that removes much of the stomach. The analysis focused on patients with severe obesity in a population that included people from ethnic minority groups^[2].

The researchers used propensity-score matching to make the groups more comparable on characteristics recorded before treatment. This method can reduce measured differences between groups, but it cannot reproduce random assignment. Patient preference and surgical eligibility can still shape both the treatment chosen and the outcome, while access, adherence, illness severity, insurance coverage, referral practices, and unrecorded clinical judgments may also differ in ways the available record cannot fully capture.

The 12-month weight-loss result

Weight was assessed at three, six, and 12 months. The authors reported statistically significant differences between the groups across those time points. At 12 months, sleeve gastrectomy was associated with 30% total weight loss and a 12 kg/m2 reduction in body mass index. Tirzepatide was associated with 12% total weight loss and a 7 kg/m2 BMI reduction^[1]. Total weight loss is the percentage of starting body weight lost, while BMI is weight adjusted for height.

Those figures should be read as outcomes in the selected matched cohort, not as fixed expectations. The abstract does not establish that patients received the same duration or follow-up support. Medication interruptions and dose changes are not fully described. Nor does the paper provide a randomized estimate of what would have happened if each patient had received the other treatment.

Why representation is part of the question

The study was designed around a diverse, urban patient population because major obesity-drug trials have not always represented the communities treated in routine practice. The authors specifically framed the comparison around eligible patients in ethnic minority groups^[2]. That makes the cohort useful, but a single-centre sample cannot stand in for every minority population, health system, or surgical programme.

Race and ethnicity can track differences in access and insurance. Referral patterns may differ, as can trust, income, and exposure to discrimination. None is a simple biological explanation for a treatment result. A useful follow-up study would report how those social and clinical factors differed between groups and whether they changed treatment completion or follow-up.

What the comparison cannot answer

This study cannot settle the long-term balance of benefit and harm. Twelve months is enough to compare early weight change, but the later course remains unknown. The abstract cannot establish durability or the extent of weight regain. It also does not resolve late surgical complications, cardiovascular outcomes, or the consequences of stopping medicine. A head-to-head analysis of adverse events and quality of life is absent, as are nutritional outcomes and total costs^[1].

The analysis also leaves an important selection question open. People who proceed to surgery have passed a clinical assessment and accepted an operation. The medication group may include people who prefer to avoid surgery. Others cannot access it or are not candidates. Matching can account for recorded differences, but those pathways may leave meaningful differences between the groups. This is comparative effectiveness research, not a simple contest between a drug and an operation.

The two treatments also involve different burdens. Sleeve gastrectomy is an operation with perioperative and nutritional considerations. Tirzepatide is a continuing prescription treatment with gastrointestinal adverse effects and contraindications described in its label. Readers can find the medicine's broader evidence and regulatory background on the tirzepatide evidence page. Neither burden can be reduced to the weight-loss percentage alone.

How to use this finding

The strongest conclusion is narrow: in this matched, retrospective, single-centre cohort, sleeve gastrectomy was associated with greater weight loss than tirzepatide through 12 months^[2]. The result supports further comparative research in populations often underrepresented in trials. It does not identify one treatment as universally superior for all eligible patients.

Treatment decisions after severe obesity depend on medical history, surgical eligibility, follow-up capacity, medicine access, patient preference, and the risks attached to each option. A qualified obesity-medicine clinician and bariatric surgical team can explain how those factors apply to an individual after reviewing the full record and discussing the patient's own goals. This article is educational and does not recommend surgery or a prescription medicine.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.